• XMT-2056, an Immunosynthen STING-agonist ADC targeting HER2, leverages an antibody that binds to a different epitope compared to that of trastuzumab and pertuzumab. • XMT-2056 showed robust anti-tumor activity after a single IV dose in xenograft and syngeneic models, including a low HER2-expressing model.

XMT-2056 is a systemically-administered Immunosynthen STING agonist antibody drug conjugate (DAR 8) that is designed to target a novel HER2 epitope (distinct from pertuzumab and trastuzumab) and locally activate STING signaling in both tumor-resident immune cells and in tumor cells (a “one-two punch”), providing the potential to treat ...

2023年4月4日 · XMT-2056 is a systemically administered Immunosynthen STING agonist antibody-drug conjugate (ADC) that targets a novel HER2 epitope and induces complete tumor regressions with a single dose in multiple tumor models.

3 天之前 · XMT-2056 exhibited concomitant immune-mediated killing of HER2-negative cells specifically in the presence of HER2-positive cancer cells, supporting the potential for activity against tumors with heterogeneous HER2 expression. The antibody does not compete for binding with trastuzumab or pertuzumab, and a benefit was observed when combining XMT ...

2023年3月13日 · The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

XMT-2056 is a systemically administered Immunosynthen STING agonist antibody-drug conjugate (ADC; drug-to-antibody ratio = 8) that targets a novel HER2 epitope and induces complete tumor regressions with a single dose in multiple tumor models.

2023年11月1日 · XMT-2056 is a novel Immunosynthen STING-agonist antibody-drug conjugate (ADC) being evaluated in a phase 1 trial (NCT05514717) for patients with HER2-high or -low solid tumors. Following a serious adverse event (SAE), investigators lowered the starting dose of XMT-2056 in the phase 1 trial.

2023年10月31日 · The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.

2025年3月3日 · XMT-2056 exhibited concomitant immune-mediated killing of HER2-negative cells specifically in the presence of HER2-positive cancer cells, supporting the potential for activity against tumors with heterogenous HER2 expression.

Upon intravenous administration of anti-HER2 STING agonist ADC XMT-2056, the anti-HER2 antibody moiety targets and binds to HER2 while the STING agonist targets and binds to STING on immune cells in the tumor microenvironment (TME).